Quest Diagnostics (DGX) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Quest Diagnostics (DGX) right now is Organic volume growth: Requisition volumes grew roughly 11 percent year over year in Q1 2026, with organic volume up about 10.8 percent. Revenue (TTM) is ~$11.5B. If that keeps playing out, the setup is favourable; the risk to it is the largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth. No one can predict where DGX trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Quest Diagnostics (DGX) higher?
1. Organic volume growth
Requisition volumes grew roughly 11 percent year over year in Q1 2026, with organic volume up about 10.8 percent. Quest is winning share in physician office, hospital outreach, and health-system reference work, and consumer-initiated testing adds an incremental channel. Volume, not price, is the primary top-line lever.
2. Acquisitions as a growth engine
M&A remains central to the strategy, with a steady stream of tuck-in lab and hospital-outreach deals. The Spectra Laboratories asset purchase from Fresenius (roughly $34 million) is expected to add about $100 million of revenue in 2026. These deals fold volume into Quest's existing network at improving margins.
3. Advanced diagnostics mix shift
Quest is pushing beyond routine testing into higher-value molecular and genomic diagnostics across oncology, neurology, and women's health, including new tests such as a myeloma assay. This mix shift supports revenue per requisition and differentiates Quest from purely commoditized lab work.
4. Productivity from AI and automation
Management credits AI and lab automation for margin gains and higher throughput. Adjusted operating margin held in the mid-teens in Q1 2026, and continued efficiency is a key reason guidance was raised even as reimbursement stays flat to down.
What could weigh on DGX?
The largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth. Labor shortages in clinical lab technologists and molecular specialists can raise costs and constrain capacity. Increased FDA oversight of laboratory-developed tests could add compliance burden. Acquisition-led growth carries integration and overpayment risk, and a large debt load from deal activity adds interest expense. Finally, the business is competitive and partly commoditized, so share losses to Labcorp, hospital in-sourcing, or specialty labs would pressure both volume and margin.
Where DGX trades today
A forecast starts from where the stock actually is. These are DGX's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for DGX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a DGX forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the DGX guide and whether DGX is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the DGX outlook
The bottom line: what is driving Quest Diagnostics (DGX) is Organic volume growth, with revenue (ttm) at ~$11.5B. If that keeps playing out the setup is favourable; the risk is the largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth. No one can predict the price, so treat any DGX forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around DGX with Walnut
Use Quest Diagnostics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Quest Diagnostics (DGX)?
+
No one can reliably predict where DGX will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Quest Diagnostics higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive DGX higher?
+
The main growth drivers are Organic volume growth; Acquisitions as a growth engine; Advanced diagnostics mix shift. Whether they play out is the real question, not a guaranteed path.
What are the risks to DGX?
+
The largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth. Labor shortages in clinical lab technologists and molecular specialists can raise costs and constrain capacity. Increased FDA oversight of laboratory-developed tests could add compliance burden. Acquisition-led growth carries integration and overpayment risk, and a large debt load from deal activity adds interest expense. Finally, the business is competitive and partly commoditized, so share losses to Labcorp, hospital in-sourcing, or specialty labs would pressure both volume and margin.
Will DGX stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Quest Diagnostics's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is DGX a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the DGX "is it a buy?" page for a framework. Walnut is not an investment adviser.
How fast is Quest growing?
+
In Q1 2026 revenue rose about 9.2 percent year over year with requisition volume up roughly 11 percent. Full-year 2026 guidance implies revenue growth of about 6.8 to 7.8 percent, driven by organic volume, acquisitions, and advanced diagnostics rather than price increases.
What drives Quest's future growth?
+
Growth drivers include organic testing volume, a steady cadence of tuck-in lab acquisitions, a mix shift toward higher-value advanced diagnostics in oncology and neurology, and margin gains from AI and lab automation. Reimbursement policy is the key external variable to watch.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.